1. China Stocks

  2. •

    Distribution services

  3. •

    Medical distributors
Kingworld Medicines Group Ltd.

Kingworld Medicines Group Ltd.

HHKEX:1110
0.38
HKD
+0.02
(+4.11%)
308.08MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.89
1.06
1.04
1.62
1.66
1.73
1.58
1.21
1.36
1.58
1.82
1.84
1.57
- -
Basic EPS, GAAP
0.08
0.06
0.05
0.07
0.08
0.07
0.07
0.02
0.05
0.04
0.06
0.07
0.02
- -
Free Cash Flow per Basic Share
-0.08
-0.01
0.14
-0.05
0.05
0.08
0.18
0.18
0.04
0.15
-0.11
0.16
0.09
- -
Dividend per Share
0.02
0.03
0.01
0.01
0.02
0.03
0.02
0.02
0.01
0.02
0.02
0.03
0.03
- -
Book Value per Share
0.73
0.92
0.95
0.84
0.89
0.91
0.97
0.95
0.99
0.99
0.99
1.09
1.04
1.04
Tangible Book Value per Share
0.73
0.92
0.62
0.54
0.62
0.67
0.76
0.76
0.82
0.84
0.85
0.93
0.89
0.89
Basic Weighted Avg Shares
623
625
685
651
623
623
621
614
623
607
592
576
586
582
Sales/Revenue/Turnover
555
660
714
1,054
1,031
1,079
978
745
847
958
1,079
1,061
917
- -
Operating Margin (%)
4.75
7.15
7.07
7.73
5.24
4.18
3.61
4.54
6.95
6.59
5.81
6.5
5.54
- -
Depreciation Expense
2
2
21
23
26
29
36
35
35
38
20
20
26
- -
Net Income, GAAP
47
38
31
47
51
41
43
12
30
23
38
42
11
- -
Effective Tax Rate (%)
25.37
22.2
23.26
24.3
20.16
26.46
27.99
28.22
26.25
35.57
34.39
22.04
32.28
- -
Profit Margin (%)
8.5
5.73
4.37
4.46
4.95
3.8
4.44
1.57
3.58
2.37
3.53
3.92
1.23
- -
Working Capital
259
367
239
161
174
143
158
159
166
83
125
93
48
48
LT Debt
- -
3
- -
- -
- -
- -
8
1
1
11
156
172
162
162
Total Equity
457
571
687
639
642
638
673
679
721
694
699
706
689
689
Return on Invested Capital (%)
8
5.54
4.46
7.43
7.14
4.95
5.83
5.56
5.43
4.74
6.15
6.39
3.81
- -
Return on Capital (%)
9.56
6.33
4.21
3.78
5.33
4.21
5.08
-1.75
1.86
1.01
2.17
1.76
-0.61
- -
Return on Common Equity (%)
10.72
7.38
5.59
8.42
9.48
7.33
7.43
1.96
5.02
3.69
6.17
6.6
1.79
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
230
266
272
LT Borrowings
162
154
149
LT Finance Leases
10
14
13
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
590
590
592
Market Capitalization
252
296
277

Working Capital

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
608
583
614
Cash, Cash Equivalents & STI
250
255
275
Accounts Receivable, Net
117
160
113
Inventories
120
113
133
Total Current Liabilities
515
510
565
Payables & Accruals
- -
- -
- -
ST Debt
230
266
272
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.09%
0.36%
-2.36%
Free Cash Flow
-38.27%
-46.61%
-42.03%
Net Income, GAAP
11%
27.51%
-72.85%
Sales/Revenue/Turnover
4.12%
4.83%
-13.55%
Total Cash Common Dividend
31.51%
53.62%
-8.26%

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
1,079
2024
- -
- -
1,061
2025
- -
- -
917

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.06
2024
- -
- -
0.07
2025
- -
- -
0.02

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.02
2024
- -
- -
0.03
2025
- -
- -
0.03

Company Description

Company Profile APIChatGPT
CEO
Li Sheng Zhao
Full Time Employees
728
Sector
Distribution services
Industry
Medical distributors
Address
Majialong Chuangxin Building Shenzhen GD China 518016
IPO Date
Nov 25, 2010
Website
kingworld.com.cn
Similar Companies
DataMeds AI, Inc. (NASDAQ:MEDS)
Selcuk Ecza Deposu Ticaret ve Sanayi A.S. (BIST:SELEC)
McKesson Corporation (NYSE:MCK)
Ibnsina Pharma (EGX:ISPH)
Cardinal Health, Inc. (NYSE:CAH)
Entero Healthcare Solutions Limited (NSE:ENTERO)
Business
Kingworld Medicines Group Limited primarily engages in the distribution and sale of branded imported pharmaceutical and healthcare products, including cough relievers, phlegm alleviators, asthma soothers, respiratory enhancers, digestive aids, intestinal health promoters, blood circulation activators, pain relievers, and flu combatants under brands such as Nin Jiom Chuan Bei Pei Pa Koa, Taiko Seirogan, Kingworld Imada Red Flower Oil, and the Culturelle probiotics product series. The company also manufactures and sells electrotherapeutic and physiotherapeutic devices, general medical examination devices, pharmaceuticals, healthcare products, general foodstuffs, Chinese medicine, and medical products. Additionally, it is involved in the distribution and sale of artwork and organization of art exhibitions, technology transfer, and property investment activities. Kingworld Medicines operates across multiple regions including the People’s Republic of China, Japan, the United States, Canada, Hong Kong, Taiwan, Thailand, the United Kingdom, Germany, Italy, Spain, and Mexico. Founded in 1996 and headquartered in Shenzhen, China, the company has expanded its product portfolio and maintained strong market presence as an omni-channel enterprise with a comprehensive supply chain in the greater healthcare products and services industry. Recently, Kingworld Medicines has reported strategic growth through increased sales of branded products like Nin Jiom and expanded its technology and device manufacturing segments, despite market challenges in demand slowdown for certain pharmaceutical imports. The company continues to reinforce its omni-channel sales strategy and broaden product offerings to strengthen its market penetration and operational resilience.